AMGN: Q3 growth broadened across the portfolio, lifting FY 2026 revenue and EPS guidance

What happened

Amgen reported third-quarter revenue growth of 8% to $10.4B and a 14% increase in non-GAAP earnings per share to $6.45. It raised its full-year 2026 revenue and earnings-per-share guidance, citing broad product growth and positive clinical results.

Confirmed

Global impact / market context

Higher guidance indicates management expects stronger sales and earnings for the year, while broad product growth suggests momentum was not limited to one offering. Positive clinical results may also support future growth, though the supplied article gives no product details or financial breakdown.

Analyst inference

Revenue and earnings-per-share growth show that sales gains translated into higher reported profit per share this quarter. The guidance increase is a forward-looking signal, not a guarantee; its effect on investor expectations depends on the revised outlook and whether growth continues.

Analyst inference

What to watch

1. The specific revised 2026 revenue and earnings-per-share ranges, which are not included here, would clarify how much management raised its expectations. Analyst inference
2. Whether product sales remain broadly positive in coming quarters could show if the reported growth is sustained rather than concentrated in a short period. Analyst inference
3. Further details on the positive clinical results could indicate whether they may support future product development or revenue; the summary does not identify the studies. Analyst inference

Evidence

• Original source link unavailable